NASDAQ:LIPO Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis $0.08 0.00 (0.00%) As of 06/3/2026 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About Lipella Pharmaceuticals Stock (NASDAQ:LIPO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LIPO alerts:Sign Up Key Stats Today's Range$0.08▼$0.1050-Day Range$0.02▼$0.1652-Week Range$0.02▼$3.17Volume121,154 shsAverage Volume23,311 shsMarket Capitalization$369.68 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. Read More Receive LIPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipella Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LIPO Stock News HeadlinesLipella Pharmaceuticals Begins Chapter 11 Bankruptcy Restructuring ProcessMarch 31, 2026 | tipranks.comLipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11March 30, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.June 4 at 1:00 AM | Porter & Company (Ad)Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen PlanusSeptember 18, 2025 | finance.yahoo.comLipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen PlanusSeptember 15, 2025 | prnewswire.comLIPO - Lipella Pharmaceuticals Inc Ordinary Shares Dividends | MorningstarJuly 18, 2025 | morningstar.comMLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - MorningstarJune 27, 2025 | morningstar.comMLipella Pharmaceuticals delisted from Nasdaq, explores relisting options amid ongoing operationsJune 27, 2025 | bizjournals.comSee More Headlines LIPO Stock Analysis - Frequently Asked Questions How have LIPO shares performed this year? Lipella Pharmaceuticals' stock was trading at $0.18 at the beginning of the year. Since then, LIPO shares have decreased by 55.6% and is now trading at $0.08. How were Lipella Pharmaceuticals' earnings last quarter? Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) released its earnings results on Wednesday, May, 14th. The company reported ($0.64) earnings per share (EPS) for the quarter. The firm had revenue of $0.13 million for the quarter. Lipella Pharmaceuticals had a negative net margin of 988.83% and a negative trailing twelve-month return on equity of 224.08%. When did Lipella Pharmaceuticals' stock split? Shares of Lipella Pharmaceuticals reverse split on Friday, November 8th 2024.A 1-8 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Lipella Pharmaceuticals IPO? Lipella Pharmaceuticals (LIPO) raised $7 million in an initial public offering on Tuesday, December 20th 2022. The company issued 1,217,391 shares at a price of $5.75-$6.25 per share. How do I buy shares of Lipella Pharmaceuticals? Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lipella Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lipella Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), MSP Recovery (LIFW), NVIDIA (NVDA), Heatwurx (PCSA), Energy Transfer (ET), Labor Smart (LTNC) and NIO (NIO). Company Calendar Last Earnings5/14/2025Today6/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LIPO CIK1347242 Weblipella.com Phone412-901-0315FaxN/AEmployees4Year Founded2005Profitability EPS (Trailing Twelve Months)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.02 million Net Margins-988.83% Pretax Margin-988.63% Return on Equity-224.08% Return on Assets-172.88% Debt Debt-to-Equity RatioN/A Current Ratio6.21 Quick Ratio6.21 Sales & Book Value Annual Sales$536.36 thousand Price / Sales0.69 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book0.05Miscellaneous Outstanding Shares4,621,000Free Float3,033,000Market Cap$369.68 thousand OptionableNot Optionable Beta1.49 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:LIPO) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersElon’s big June 12 announcementJune 12 is the reported deadline for a major announcement tied to Elon Musk's so-called 'Project Unlimited' - ...Weiss Ratings | SponsoredA New Approach to Affordable Housing75% of U.S. households cannot afford a median-priced new home. BOXABL's factory-built, foldable homes are desi...BOXABL | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredWhere did Vanguard quietly put $101 billion?Tech investor George Gilder spent 40 years identifying paradigm shifts before they went mainstream - flagging ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
